



King Saud University

Saudi Pharmaceutical Journal

www.ksu.edu.sa
www.sciencedirect.com



ORIGINAL ARTICLE

New acyclic secondary metabolites from the biologically active fraction of *Albizia lebbek* flowers

Shaza M. Al-Massarani^a, Ali A. El Gamal^{a,b,*}, Mohamed F. Abd El Halim^a,
Mansour S. Al-Said^a, Maged S. Abdel-Kader^c, Omer A. Basudan^a,
Saleh I. Alqasoumi^a

^a Pharmacognosy Department, Faculty of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

^b Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, P.O. 35516, Mansoura, Egypt

^c Pharmacognosy Department, College of Pharmacy, Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia

Received 24 April 2016; accepted 16 May 2016

KEYWORDS

Albizia lebbek flowers;
Hepatoprotective;
Aroma precursors;
Farnesol derivatives;
Dihydrosqualene derivatives

Abstract The total extract of *Albizia lebbek* flowers was examined *in vivo* for its possible hepato-protective activity in comparison with the standard drug silymarin at two doses. The higher dose expressed promising activity especially in reducing the levels of AST, ALT and bilirubin. Fractionation via liquid–liquid partition and reexamination of the fractions revealed that the *n*-butanol fraction was the best in improving liver biochemical parameters followed by the *n*-hexane fraction. However, serum lipid parameters were best improved with CHCl₃ fraction. The promising biological activity results initiated an intensive chromatographic purification of *A. lebbek* flowers fractions. Two compounds were identified from natural source for the first time, the acyclic farnesyl sesquiterpene glycoside 1-O-[6-O- α -L-arabinopyranosyl- β -D-glucopyranoside]-(2*E*,6*E*)-farnesol (**6**) and the squalene derivative 2,3-dihydroxy-2,3-dihydrosqualene (**9**), in addition to eight compounds reported here for the first time from the genus *Albizia*; two benzyl glycosides, benzyl 1-O- β -D-glucopyranoside (**1**) and benzyl 6-O- α -L-arabinopyranosyl β -D-glucopyranoside (**2**); three acyclic monoterpene glycosides, linalyl β -D-glucopyranoside (**3**) and linalyl 6-O- α -L-arabinopyranosyl- β -D-glucopyranoside (**4**); (2*E*)-3,7-dimethylocta-2,6-dienoate-6-O- α -L-arabinopyranosyl- β -D-glucopyranoside (**5**), two oligoglycosides, *n*-hexyl- α -L-arabinopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (creoside) (**7**) and *n*-octyl α -L-arabinopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (rhodiooctanoside) (**8**); and ethyl fructofuranoside (**10**). The structures of the isolated compounds were elucidated based on extensive

* Corresponding author at: Pharmacognosy Department, Faculty of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

<http://dx.doi.org/10.1016/j.jsps.2016.05.006>

1319-0164 © 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Al-Massarani, S.M. et al., New acyclic secondary metabolites from the biologically active fraction of *Albizia lebbek* flowers. Saudi Pharmaceutical Journal (2016), <http://dx.doi.org/10.1016/j.jsps.2016.05.006>

examination of their spectroscopic 1D and 2D-NMR, MS, UV, and IR data. It is worth mentioning that, some of the isolated linalol glycoside derivatives were reported as aroma precursors.

© 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

The genus *Albizia* (Fabaceae), embraces around 150 species, mostly trees and shrubs native to warm areas of Asia and Africa (Migahed, 1996). It is widely cultivated in tropical and subtropical regions as an ornamental plant. A perusal of the literature revealed that plants belonging to genus *Albizia* have great medicinal values. *A. anthelmintica* A. Brogne is used for the treatment of malaria and febrile convulsions (Carpani et al., 1989; Johns et al., 1994), while the leaves, boiled with water, are given by traditional healers in Dar es Salaam, Tanzania, for the treatment of epilepsy (Moshi et al., 2005). On the other hand, the bark of *Albizia odoratissima* is used to treat cough, bronchitis, rheumatism and diabetes (Kumar et al., 2011). Seeds of *Albizia amara* are used in the treatment of piles, diarrhea and gonorrhoea (Gundamaraju et al., 2014).

Since the fifties of the last century, genus *Albizia* has been a rich source of several classes of bioactive secondary metabolites including saponins, tannins, alkaloids, flavonoids and phenolic glycosides (El-Mousallamy, 1998; Kang et al., 2007; Sanjay, 2003; Varshney and Farooq, 1952). Recently, an antitumor triterpene saponin julibroside J₂₈, isolated from the stem bark of *Albizia julibrissin* has displayed significant, *in vitro*, antitumor activity against PC-3M-1E8, Bel-7402 and HeLa cancer cell lines at 10 µM assayed by SRB method (Liang et al., 2005).

Albizia lebeck L. is one of the most common species of *Albizia* worldwide, known by various names such as Indian siris, flea tree, frywood, koko and Laback in Arabic. The tree was imported to Saudi Arabia from India, years ago, as an ornamental tree, well adapted to the hot environmental conditions of Najd state in the central region of Saudi Arabia (El Gamal et al., 2015).

It is usually flowering, between April and September, with cream-colored fragrant hermaphroditic flowers (Migahed, 1996). The plant is well-known, in traditional folk medicine, for the treatment of various ailments in several areas around the world. In Ayurveda, all parts of the tree including roots, leaves, bark and flowers are used to cure asthma and other inflammatory conditions such as, arthritis and burns (Ayurvedic Pharmacopoeia of India, 2001). In traditional Chinese medicine the flowers are commonly used to treat anxiety, depression and insomnia (Kang et al., 2007). The decoction of the flower in a dose of 50 mg/kg induces muscle relaxation and can protect the guinea pig against histamine-induced bronchospasm (Tripathi and Das, 1977).

In our previous research on *A. lebeck*, we found that different fractions from the flowers of *A. lebeck* possessed anti-pyretic, analgesic, estrogenic and anti-inflammatory activities (Farg et al., 2013). Our earlier phytochemical study of the alcoholic extract of the flowers led to the isolation of taraxerol triterpenes, ceramide derivatives and two flavonoids, in addition to a novel β-lactam derivative, albactam, which was also evaluated for platelet anti-aggregatory effect (El Gamal et al., 2015).

In view of the versatile biological activities of this plant and as a part of our continuing interest in identifying biologically active drug leads from natural sources, we conducted this research with the aim of discovering new compounds with hepatoprotective potential.

2. Materials and methods

2.1. General experimental procedures

¹H and ¹³C NMR spectra were recorded at NMR Unit at the College of Pharmacy, Sattam Bin Abdulaziz University on a UltraShield Plus 500 MHz (Bruker) spectrometer operating at 500 MHz for proton and 125 MHz for carbon, respectively. The chemical shift values are reported in δ (ppm) relative to the internal standard TMS or residual solvent peak, and the coupling constants (*J*) are reported in Hertz (Hz). 2D-NMR experiments (COSY, HSQC, HMBC and NOESY) were obtained using standard Bruker program. Jeol JMS-700 High Resolution Mass Spectrophotometer was used for accurate mass determination. Electron Impact mode with ionization energy of 70 eV was accustomed. Direct probe, temperature ramp setting was used with initial temperature 50 °C; increasing 32 °C per minute and final temperature 350 °C set up, and resolution was adjusted to 10k. Thin layer chromatography (TLC) was performed on pre-coated silica gel F₂₅₄ plates (E. Merck, Darmstadt, Germany); detection was done at 254 nm and by spraying with p-anisaldehyde/H₂SO₄ reagent followed by heating at 110 °C for 1–2 min. Centrifugal preparative thin layer chromatography (CPTLC) was performed on chromatotron (Harrison Research, Palo Alto, California, CA, USA). Plates coated with 2 mm of silica gel 60, 0.04–0.06 mm were used. All solvents used were of analytical grade. Silymarin was purchased from Sigma Aldrich (St. Louis, USA).

2.2. Plant materials

The flowers of *A. lebeck* Linn. were collected in April, 2011, from Riyadh, kingdom of Saudi Arabia. The plant was identified by Dr. Mohammed Yusuf, taxonomist of the Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. A voucher specimen (# 16182) has been deposited at the Pharmacognosy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

2.3. Extraction, fractionation and isolation

The air-dried powdered flowers of *A. lebeck* (1 kg) were extracted with 80% ethanol (3 × 4 L) at room temperature. The pooled extracts were concentrated under reduced pressure using rotatory evaporator to get a dark brownish residue

(250 g), part of which (100 g) was suspended in methanol (400 mL) and filtered to remove the precipitated insoluble part. The dried methanol-soluble fraction (55 g) was dissolved in 40% ethanol and successively partitioned with *n*-hexane (300 mL × 4), chloroform (300 mL × 4), ethyl acetate (300 mL × 4) and *n*-butanol (300 mL × 4) to provide the corresponding fractions. The *n*-hexane fraction (12 g) was subjected to column chromatography on pre-packed silica gel column (35 mm i.d. × 350 mm) using *n*-hexane-ethyl acetate gradient; collected fractions were examined with TLC and similar fractions were pooled together. The fraction eluted with *n*-hexane/EtOAc (20/80) was further purified by subjecting to RP-18 column (120 g × 60 cm × 3 cm) using MeOH/CH₃CN, 10/90 to give an almost pure compound which was further purified on the chromatotron using solvent system 1% acetone-CHCl₃ to give compound **9** (25 mg).

The chloroform fraction (13 g) was applied on a silica gel column using CHCl₃/MeOH gradient and collected fractions were grouped to obtain four main subfractions: A (3.7 g), B (3.4 g), C (2.6 g) and D (3.3 g). Fraction A was rechromatographed on a RP-18 column (MeOH-H₂O, gradient) to yield compound **10** (15 mg). Fraction B was subjected to purification by chromatotron (8% MeOH/CHCl₃), followed by RP-18 column chromatography (MeOH-H₂O, 65:35) to yield compound **4** (23 mg). Fraction C was further purified on a RP-18 column (MeOH-H₂O, 65:35) to give compound **5** (8 mg), while compound **6** (19 mg) was obtained by RP-18 column (10% MeOH/H₂O) of fraction D.

The *n*-butanol fraction (10 g) was chromatographed on Diaion HP-20 column, using MeOH/H₂O gradient to afford two main subfractions (i and ii). Sub fraction i, eluted with 40% MeOH/H₂O was further subjected to column chromatography (CHCl₃/MeOH, gradient) to afford compounds **1–3** (using 9–15% MeOH/CHCl₃ as eluents respectively). Sub fraction ii, eluted with 60% MeOH/H₂O was further subjected to RP-18 column chromatography (100 g × 50 cm × 3 cm, MeOH/H₂O gradient) to afford compounds **7** and **8** (eluted with 50% and 65% MeOH/H₂O respectively).

2.4. Animals

Wistar male albino rats weighing 150–200 g, almost the same age (8–10 weeks), obtained from the Experimental Animal Care Center, College of Pharmacy, King Saud University, Riyadh, were used. The animals were kept under constant temperature (22 ± 2 °C), humidity (55%) and light/dark conditions (12/12 h). They had *ad libitum* access to a dry commercial diet and free access to drinking water (Abdel-Kader et al., 2010). The procedures and experiments used in this research were approved by the Ethics Committee of the College of Pharmacy, King Saud University.

2.5. Hepatoprotective activity

The male albino rats were randomly assigned into four groups (5 animals each). Group IV was divided into eight sub groups of five animals each. Group I received only normal saline and served as control. Groups I–IV received single dose of CCl₄ (1.25 mL/kg body weight). Group II received CCl₄ treatment only. Group III administered silymarin at a dose of 10 mg/kg p.o. The sub groups of were treated with 200, 400 mg/kg

of the total extract, 50 and 100 mg/kg of the different fractions. Treatment started 6 days prior to CCl₄ and continued till day seven. After 24 h, following CCl₄ administration in day 7, the animals were sacrificed using ether anesthesia. Blood samples were collected by heart puncture and the serum was separated to evaluate the biochemical parameters (Abdel-kader and Alqasoumi, 2008).

2.6. Determination of AST, ALT, GGT, ALP, bilirubin, cholesterol, triglycerides, HDL, LDL and VLDL levels

Five biochemical parameters, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl-transpeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin were estimated, as reflection of liver function, by reported method (Edwards and Bouchier, 1991). The enzyme activities were measured using diagnostic strips (Reflotron®, ROCHE) and were read on a Reflotron®Plus instrument (ROCHE). TG (Foster and Dunn, 1973), TC (Zlatkis et al., 1953), HDL-C (Burstein et al., 1970), LDL-C and VLDL (Friedwald et al., 1972) were assessed using Roche Diagnostics Kits.

2.7. Determination of non-protein sulfhydryl groups (NP-SH), malonaldehyde (MDA) and total protein (TP)

The livers were separately cooled in a beaker immersed in an ice bath. The tissues were homogenized in 0.02 M ethylenediaminetetraacetic acid (EDTA) in a Potter-Elvehjem type C homogenizer.

Homogenate equivalent of 100 mg tissues was used for the measurements. Non-protein sulfhydryl groups (NP-SH) and MDA were quantified spectrophotometrically as previously described (Sedlak and Lindsay, 1968).

Total protein was determined according to the method of Lowry et al. (1951) Homogenates were treated with 0.7 mL of Lowry's solution, mixed and incubated for 20 min in dark at room temperature. Diluted Folin's reagent (1 mL) was then added and samples were incubated at room temperature in dark for 30 min. The absorbance of the resulted solutions was then measured at 750 nm (Lowry et al., 1951).

2.8. Statistical analyses

Results are expressed as Mean ± Standard Error (SE) of mean. Statistical analysis was achieved, using a one-way analysis of variance (ANOVA). When, the *F*-value was found statistically significant (*p* < 0.05), further comparisons among groups were made using Dunnett's multiple comparisons test. All statistical analyses were performed using SPSS software 17.0 (Released Aug. 23, 2008), Chicago, USA.

3. Results

Phytochemical study of *A. lebbek* flowers resulted in the isolation of ten compounds, benzyl 1-O-β-D-glucopyranoside (**1**), benzyl 6-O-α-L-arabinopyranosyl β-D-glucopyranoside (**2**), linalyl β-D-glucopyranoside (**3**), linalyl 6-O-α-L-arabinopyranosyl β-D-glucopyranoside (**4**), (2*E*)-3,7-dimethylocta-2,6-dienoate-6-O-α-L arabinopyranosyl-β-D-glucopyranoside (**5**), 1-O-[6-O-

α -L-arabinopyranosyl- β -D-glucopyranoside]-(2*E*,6*E*)-farnesol (6) *n*-hexyl- α -L-arabinopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (creoside) (7), *n*-octyl α -L-arabinopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (Rhodiooctanoside) (8), 2,3-dihydroxy-2,3-dihydrosqualene (9) and ethyl fructofuranoside (10). The structures of the compounds are presented in Fig. 1.

The total alcoholic extract, *n*-hexane, chloroform (CHCl₃) and *n*-butanol fractions were tested for hepatoprotective effect against CCl₄ induced toxicity. The results are shown in Tables 4 and 5.

3.1. The physical and spectral data of compounds 1–10

3.1.1. Benzyl 1-*O*- β -D-glucopyranoside (1)

C₁₃H₁₈O₆; white solid; ¹H NMR (500 MHz, MeOD): δ_{H} 7.43 (br d, H-2/6), 7.33 (br t H-3/5), 7.28 (m, H-4), 4.93 (d, $J = 11.9$ Hz, H-7a), 4.70 (d, $J = 11.9$ Hz, H-7b), 4.34 (d, $J = 7.5$ Hz, H-1'), 3.20 (m, H-2'), 3.35 (m, H-3'), 3.36 (m, H-4'), 3.17 (m, H-5'), 3.80 (dd, $J = 11.8, 2.5$ Hz, H-6'-a), 3.65 (dd, $J = 11.8, 5.6$ Hz, H-6'-b); ¹³C NMR (125 MHz, MeOD): δ_{C} 139.1 (C-1), 129.4 (C-2/6), 129.4 (C-3/5), 128.8 (C-4), 71.8 (C-7), 103.3 (C-1'), 75.1 (C-2'), 78.0 (C-3'), 71.8 (C-4'), 78.1 (C-5'), 62.8 (C-6'); HREIMS m/z 270.2780 [M⁺].

3.1.2. Benzyl-6-*O*- α -L-arabinopyranosyl β -D-glucopyranoside (2)

C₁₈H₂₆O₁₀; white solid; ¹H NMR (500 MHz, MeOD): δ_{H} 7.43 (br d, H-2/6), 7.33 (br t H-3/5), 7.28 (m, H-4), 4.93 (d, $J = 11.9$ Hz, H-7a), 4.70 (d, $J = 11.9$ Hz, H-7b), 4.35 (d, $J = 8.0$ Hz, H-1'), 3.22 (t, $J = 8.1$ Hz, H-2'), 3.42 (d, $J = 2.3$ Hz, H-3'), 3.43 (m, H-4'), 3.44 (m, H-5'), 4.33 (dd, $J = 11.0, 5.7$ Hz, H-6'a), 3.75 (dd, $J = 11.0, 5.6$ Hz, H-6'b), 4.34 (d, $J = 7.0$ Hz, H-1''), 3.59 (dd, $J = 9.0, 7.1$ Hz, H-2''), 3.64 (dd, $J = 9.1, 3.0$ Hz, H-3''), 3.95 (m, H-4''), 3.89 (dd, $J = 13.0, 2.2$ Hz, H-5'a), 3.65 (br d, $J = 12.4$ Hz,

H-5''b); ¹³C NMR (125 MHz, MeOD): δ_{C} 139.1 (C-1), 129.4 (C-2/6), 129.3 (C-3/5), 128.9 (C-4), 72.0 (C-7), 103.4 (C-1'), 75.1 (C-2'), 77.9 (C-3'), 71.6 (C-4'), 76.9 (C-5'), 69.6 (C-6'), 105.3 (C-1''), 72.4 (C-2''), 74.2 (C-3''), 69.6 (C-4''), 66.9 (C-5''); HREIMS m/z 402.1526 [M⁺].

3.1.3. Linalyl- β -D-glucopyranoside (3)

C₁₆H₂₈O₆; white viscous liquid; ¹H NMR (500 MHz, MeOD): δ_{H} 5.17 (d, $J = 11.3$ Hz, H-1-a), 5.22 (d, $J = 18.0$ Hz, H-1-b), 6.07 (dd, $J = 17.7, 11.0$ Hz, H-2), 1.64 (m, H-4), 2.04 (m, H-5), 5.11 (br t, $J = 7.0$ Hz, H-6), 1.68 (s, H-8), 1.61 (s, H-9), 1.35 (s, H-10), 4.33 (d, $J = 7.4$ Hz, H-1'), 3.18 (m, H-2'), 3.34 (m, H-3'), 3.36 (m, H-4'), 3.16 (m, H-5'), 3.80 (dd, $J = 11.9, 2.3$ Hz, H-6'-a), 3.65 (dd, $J = 11.9, 5.5$ Hz, H-6'-b); ¹³C NMR (125 MHz, MeOD): δ_{C} 115.1 (C-1), 144.5 (C-2), 81.5 (C-3), 41.6 (C-4), 23.5 (C-5), 125.8 (C-6), 32.2 (C-7), 23.7 (C-8), 26.0 (C-9), 17.9 (C-10), 99.2 (C-1'), 75.1 (C-2'), 78.2 (C-3'), 71.7 (C-4'), 77.6 (C-5'), 62.9 (C-6'); HREIMS m/z 316.1886 [M⁺].

3.1.4. Linalyl-6-*O*- α -L-arabinopyranosyl- β -D-glucopyranoside (4)

C₂₁H₃₆O₁₀; viscous liquid; ¹H NMR (500 MHz, MeOD): δ_{H} 5.22 (d, $J = 11.3$ Hz, H-1a), 5.17 (d, $J = 11.3$ Hz, H-1b), 6.09 (dd, $J = 17.7, 11.0$ Hz, H-2), 1.56 (m, H-4a), 1.62 (m, H-4b), 2.07 (m, H-5a), 2.04 (m, H-5b), 5.11 (br t, $J = 7.0$ Hz, H-6), 1.68 (s, H-8), 1.61 (s, H-9), 1.35 (s, H-10), 4.35 (d, $J = 7.9$ Hz, H-1'), 3.20 (t, $J = 8.0$ Hz, H-2'), 3.40 (m, H-3'), 3.43 (m, H-4'), 3.43 (m, H-5'), 4.33 (dd, $J = 11.0, 5.7$ Hz, H-6'a), 3.75 (dd, $J = 11.0, 5.5$ Hz, H-6'b), 4.33 (d, $J = 7.0$ Hz, H-1''), 3.60 (dd, $J = 9.0, 7.0$ Hz, H-2''), 3.63 (dd, $J = 9.1, 3.0$ Hz, H-3''), 3.93 (m, H-4''), 3.88 (dd, $J = 13.0, 2.2$ Hz, H-5'a), 3.66 (br d, $J = 12.4$ Hz, H-5'b); ¹³C NMR (125 MHz, MeOD): δ_{C} Table 2; HREIMS m/z 448.2308.




Figure 1 Chemical structures of the isolated compounds from *A. lebeck* flowers.

3.1.5. (2*E*)-3,7-dimethylocta-2,6-dienoate-6-*O*- α -*L*-arabinopyranosyl- β -*D*-glucopyranoside (**5**)

C₂₁H₃₄O₁₁; colorless amorphous powder; ¹H NMR Table 1; ¹³C NMR Table 2; HREIMS *m/z* 462.2101 [M⁺].

3.1.6. 1-*O*-[6-*O*- α -*L*-arabinopyranosyl β -*D*-glucopyranoside] – (2*E*,6*E*)-farnesol (**6**)

C₂₆H₄₄O₁₀; viscous liquid; ¹H NMR Table 1; ¹³C NMR Table 2; HREIMS *m/z* 516.2934 [M⁺].

3.1.7. Hexyl- α -*L*-arabinopyranosyl-(1 \rightarrow 6)- β -*D*-glucopyranoside (Creoside IV) (**7**)

C₁₇H₃₂O₁₀; colorless amorphous powder; ¹H NMR Table 1; ¹³C NMR Table 2; HREIMS *m/z* 396.1995 [M⁺].

3.1.8. Octyl- α -*L*-arabinopyranosyl-(1 \rightarrow 6)- β -*D*-glucopyranoside (rhodiocostanoside) (**8**)

C₁₉H₃₆O₁₀; white amorphous powder; ¹H NMR Table 1; ¹³C NMR Table 2; HREIMS *m/z* 424.2308 [M⁺].

3.1.9. 2,3-Dihydroxy-2,3-dihydrosqualene (**9**)

C₃₀H₅₂O₂; oily; ¹H NMR (500 MHz, MeOD): δ _H 1.16 (s, H-1), 1.22 (s, H-25), 1.60–1.70 (18 H, s, CH₃-24,26–30), 1.98–2.22 (m, CH₂-4,5,8,9,12,13,16,17,20,21), 5.22 (H-7), 3.37 (d, *J* = 7.5 Hz, H-3), 5.12–5.22 (5H, t, *J* = 6.1 Hz, C-H-7,11,14,18,22); ¹³C NMR (125 MHz, MeOD): δ _C 23.2 (C-1), 73.1 (C-2), 78.3 (C-3), 29.7 (C-4), 36.8 (C-5), 135.2 (C-6), 124.3 (C-7), 26.8 (C-8), 39.8 (C-9), 134.9 (C-10), 124.4 (C-

Table 2 ¹³C NMR data of compounds **1–8** (125 MHz, MeOD).

	1	2	3	4	5	6	7	8
1	139.1	139.1	115.1	115.1	166.5	66.7	71.1	71.1
2	129.4	129.4	144.5	144.3	115.9	121.6	30.8	30.8
3	129.3	129.3	81.5	81.5	164.5	142.4	26.8	27.1
4	128.8	128.9	41.6	41.7	42.0	40.8	32.9	30.6
5	129.3	129.3	23.5	23.8	27.1	27.5	23.7	30.4
6	129.4	129.4	125.8	125.8	124.1	125.2	14.4	33.0
7	71.8	72.0	132.2	132.2	133.6	136.3	–	23.7
8	–	–	23.7	26.0	25.9	40.9	–	14.5
9	–	–	26.0	23.7	17.8	27.9	–	–
10	–	–	17.9	17.9	19.3	125.5	–	–
11	–	–	–	–	–	132.1	–	–
12	–	–	–	–	–	26.1	–	–
13	–	–	–	–	–	17.9	–	–
14	–	–	–	–	–	16.3	–	–
15	–	–	–	–	–	16.8	–	–
1'	103.3	103.4	99.2	99.3	95.2	103.0	104.4	104.4
2'	75.1	75.1	75.1	75.1	77.9	75.0	75.2	75.2
3'	78.0	77.9	78.2	78.2	77.6	77.9	78.1	78.1
4'	71.8	71.6	71.7	71.7	73.9	71.5	71.7	71.7
5'	78.1	76.9	77.6	76.4	71.2	76.8	76.9	76.8
6'	62.8	69.6	62.9	69.4	69.2	69.5	69.6	69.5
1''	–	105.3	–	104.9	104.8	105.1	105.2	105.2
2''	–	72.4	–	72.5	72.4	72.4	72.5	72.5
3''	–	74.2	–	74.2	74.2	74.2	74.4	74.4
4''	–	69.6	–	69.4	69.6	69.4	69.5	69.6
5''	–	66.9	–	66.4	66.8	66.8	66.8	66.8

Table 1 ¹H NMR data of compounds **5–8** (500 MHz, MeOD).

	5	6	7	8
1	–	4.21 (dd, <i>J</i> = 11.8, 7.5 Hz); 4.36 (dd, <i>J</i> = 9.3, 6.5 Hz)	4.20 (dd, <i>J</i> = 12.4, 7.6 Hz) 4.35 (dd, <i>J</i> = 12.4, 6.9 Hz)	3.83 (m)
2	5.76 (s)	5.41 (t, <i>J</i> = 6.5 Hz)	1.61 (m)	1.61 (m)
3	–	–	1.37 (m)	1.22–1.47 (m)
4	2.23 (m)	2.08 (m)	1.34 (m)	–
5	2.23 (m)	2.16 (m)	1.34 (m)	–
6	5.20 (dd, <i>J</i> = 6.6, 6.9 Hz)	5.14 (m)	0.91 (t, <i>J</i> = 6.8 Hz)	–
7	–	–	–	–
8	1.70 (s)	1.99 (m)	–	0.90 (t, <i>J</i> = 6.9 Hz)
9	1.64	2.10 (m)	–	–
10	2.20 (s)	5.11 (m)	–	–
11	–	–	–	–
12	–	1.69 (s)	–	–
13	–	1.62 (s)	–	–
14	–	1.63 (s)	–	–
15	–	1.72 (s)	–	–
1'	5.49 (d, <i>J</i> = 8.2 Hz)	4.32 (d, <i>J</i> = 7.9 Hz)	4.26 (d, <i>J</i> = 8.0 Hz)	4.22 (d, <i>J</i> = 8.0 Hz)
2'	3.55 (m)	3.23 (t, <i>J</i> = 8.2 Hz)	3.18 (dd, <i>J</i> = 8.2, 8.9 Hz),	3.19 (m)
3'	3.46 (dd, <i>J</i> = 8.9, 8.9 Hz)	3.40 (d, <i>J</i> = 2.3 Hz)	3.34 (m)	3.32 (m)
4'	3.53 (m)	3.42 (m)	3.34 (m)	3.32 (m)
5'	3.39 (m)	3.43 (m)	3.42 (m)	3.40 (m)
6'	4.12 (dd, <i>J</i> = 11.2, 2.1 Hz) 3.75 (dd, <i>J</i> = 11.2, 5.3 Hz)	4.11 (dd, <i>J</i> = 11.5, 1.9 Hz) 3.76 (dd, <i>J</i> = 11.1, 5.8 Hz)	4.09 (brd, <i>J</i> = 10.0 Hz) 3.73 (m)	4.09 (brd, <i>J</i> = 11.4 Hz) 3.77 (d, <i>J</i> = 6.6 Hz)
1''	4.30 (d, <i>J</i> = 6.8 Hz)	4.33 (d, <i>J</i> = 6.8 Hz)	4.32 (d, <i>J</i> = 6.5 Hz)	4.31 (d, <i>J</i> = 6.7 Hz)
2''	3.57 (dd, <i>J</i> = 6.4, 8.5 Hz)	3.60 (dd, <i>J</i> = 9.3, 7.0 Hz)	3.59 (m)	3.62 (m)
3''	3.37 (dd, <i>J</i> = 8.2, 8.7 Hz)	3.65 (dd, <i>J</i> = 9.3, 3.1)	3.53 (m)	3.53 (m)
4''	3.81 (m)	3.97 (m)	3.80 (m)	3.82 (m)
5''	3.87 (dd, <i>J</i> = 3.2, 12.5 Hz) 3.53 (dd, <i>J</i> = 5.3, 11.2 Hz)	3.90 (dd, <i>J</i> = 12.6, 2.1 Hz) 3.66 (brd, <i>J</i> = 12.4 Hz)	3.85 (m) 3.52 (m)	3.83 (m)

11), 28.3 (C-12), 26.4 (C-13), 124.4 (C-14), 135.0 (C-15), 39.8 (C-16), 26.7 (C-17), 125.1 (C-18), 134.9 (C-19), 39.8 (C-20), 26.7 (C-21), 124.2 (C-22), 131.3 (C-23), 23.3 (C-24), 25.7 (C-25), 15.9 (C-26), 16.0 (C-27), 16.0 (C-28), 16.1 (C-29), 17.7 (C-30); HREIMS m/z 444.3967 $[M^+]$.

3.1.10. 4-Ethyl fructofuranoside (10)

$C_8H_{16}O_6$; viscous liquid; 1H NMR (500 MHz, MeOD): δ_H 3.90 (m, H-1), 3.70 (dd, $J = 2.8, 3.0$ Hz, H-2), 4.04 (d, $J = 2.8$ Hz, H-3), 3.66, 3.90 (dd 2.5, 12.00 CH_2 -5), 3.56, 3.77 (m, CH_2 -6), 3.57 (m, $J = 7.4$ Hz CH_2 -1'), 1.20 (t, $J = 7.5$ Hz CH_3 -2'), 5.15 ^{13}C NMR (125 MHz, MeOD): δ_C 84.1 (C-1), 78.6 (C-2), 83.0 (C-3), 109.0 (C-4), 61.5 (C-5), 62.7 (C-6), 57.8 (C-1'), 16.1 (C-2'); HREIMS m/z 208.0947 $[M^+]$.

4. Discussion

The administration of CCl_4 causes damage of the hepatocytes which is reflected by increase in the biochemical parameter levels such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and total bilirubin (Table 3). Investigation of the curative potentials of the total alcoholic extract at two doses revealed that pretreatment of rats with 400 mg/kg provided protection comparable to that of silymarin. The levels of AST, ALT, GGT and bilirubin were reduced by 52.01%, 33.67%, 29.67% and 48.05% respectively. The least improvement was observed in the level of ALP (18.89%). All results were highly significant ($p < 0.001$) (Table 3). Liquid-Liquid fractionation of the total extracts with *n*-hexane, $CHCl_3$ and *n*-butanol and evaluation of the hepatoprotective potential of the fractions at 50 and 100 mg/kg revealed that the *n*-butanol fraction is the most active in reduction of the levels of AST (36.54%), ALT (48.56%), MDA (1.82 ± 0.20) and restoring the levels of NP-SH (4.50 ± 0.30) and total protein (82.19 ± 0.19) ($p < 0.001$ and $p < 0.01$) (Tables 3 and 5). In the second place in improving these parameters comes the *n*-hexane fraction (Tables 3 and 5). However, the $CHCl_3$ fraction was superior in the improvement of blood lipid picture (Table 4). Cholesterol, triglycerides, HDL, LDL and VLDL were improved significantly ($p < 0.001$) following the treatment of the rats with 100 mg/kg.

Phytochemical analysis of the *n*-hexane, chloroform and *n*-butanol fractions obtained from the flowers of *A. lebbek* led to the isolation of two benzyl glycosides, benzyl 1-O- β -D-glucopyranoside (1) (De Rosa et al., 1996; Wen et al., 2012) and benzyl 6-O- β -L-arabinopyranosyl β -D-glucopyranoside (2) (Chassagne et al., 1996); three acyclic monoterpene glycosides, linalyl β -D-glucopyranoside (3) (Moon et al., 1994), linalyl 6-O- α -L-arabinopyranosyl- β -D-glucopyranoside (4) (Chassagne et al., 1996; Pabst et al., 1991) and (2E)-3,7-dimethylocta-2,6-dienoate-6-O- α -L-arabinopyranosyl- β -D-glucopyranoside (5) (Yang et al., 2013), an acyclic sesquiterpene glycoside 1-O-[6-O- α -L-arabinopyranosyl- β -D-glucopyranoside]-(2E,6E)-farnesol (6) (Magid et al., 2005, 2008) in addition to creoside IV (7) (Nakamura et al., 2008), octyl α -L-arabinopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (rhodiocyanoside) (8) (Yoshikawa et al., 1996), the squalene derivative, 2,3-dihydroxy-2,3-dihydrosqualene (9) (Brown and Martens, 1977) and ethyl fructofuranoside (10) (Liu

et al., 2012; Lu et al., 2013) which were identified using 1D and 2D-NMR and HREIMS and in correlation with known compounds. The compounds 6 and 9 are reported here for the first time from natural sources. On the other hand and from the chemotaxonomic point of view, the sugar part of the isolated bioside glycosides consists of α -L-arabinopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside which might be considered as chemotaxonomic marker for *A. lebbek*.

It is noteworthy that linalyl β -D-glucopyranoside (3) and linalyl 6-O- α -L-arabinopyranosyl- β -D-glucopyranoside (4) were reported as aroma precursors from *Jasminum sambac* and passion fruit (*Passiflora edulis*), respectively (Chassagne et al., 1996; Moon et al., 1994). On the other hand, ethyl fructofuranoside (10) is formed as a by-product by the *Wickerhamomyces anomala*, a yeast strain capable of selective utilization of fructooligosaccharides (FOSs) syrup (Lu et al., 2013).

Compound 6 was obtained as a viscous liquid. HREIMS of compound 6 showed a molecular ion peak at m/z 516.2934 $[M^+]$ suggesting the molecular formula $C_{26}H_{44}O_{10}$ and 5 degrees of unsaturation. Careful examination of NMR spectra for compound 6 revealed the presence of a farnesyl type sesquiterpene glycoside. Its ^{13}C NMR and DEPT spectrum (Table 1) exhibited 26 carbons including four olefinic methyls, seven methylenes, twelve methines nine of which are oxygenated and three quaternary carbons. The aglycone part was proved to be a farnesyl type sesquiterpene by four olefinic methyls observed in the NMR spectra, at δ_H 1.62, 1.63, 1.69 and 1.72, connected, in the HSQC, to carbons at δ_C 17.9, 16.3, 26.1 and 16.8 ppm; assigned for Me-13, Me-14, Me-12 and Me-15 respectively. Long range coupling was observed between the olefinic protons at δ_H 5.11 ppm (H-10, m) and Me-12 and Me-13; and 5.14 (H-6, m) and Me 14; and 5.41 (H-2, t) with Me-15. The presence of oxymethylene at C-1 was clarified by one pair of two coupled oxygenated protons at δ_H 4.21 ppm (H-1a, dd, $J = 11.8, 7.6$ Hz), 4.36 ppm (H-1b, dd, $J = 9.3, 6.5$ Hz), both showing cross peak correlations with the olefinic proton at δ_H 5.41 (H-2, t, $J = 6.45$ Hz).

Moreover, NMR showed the presence of four upfield methylene protons at δ_H 2.08 (H₂-4, m), 2.16 (H₂-5, m), 1.99 (H₂-8, m) and 2.10 ppm (H₂-9, m). The above mentioned spectral data together with 15 carbon atoms ascribed by ^{13}C NMR and DEPT experiments as 4 methyls, 5 methylenes, three olefinic methines at δ_C 121.6, 125.2 and 125.5 ppm assigned for C-2, C-6 and C-10 respectively and three quaternary carbons at δ_C 132.2, 136.3 and 142.5 assigned for carbons 11, 7 and 3 respectively confirmed the presence of acyclic farnesyl type sesquiterpene. The ^{13}C NMR chemical shift values for the olefinic methyls, Me-14 and Me-15 observed at δ_C 16.3 and 16.8 ppm and those for the two methylene at C-4 and C-8 appeared at δ_C 40.8 and 40.9 ppm, respectively are closely similar for those reported for (2E,6E)-farnesol (Kasai et al., 1986) while the C-12 resonated at δ_C 20.1 ppm. The chemical structure of the sugar part of the molecule was confirmed to be a bioside of β -D-glucose and α -L-arabinose based on the data obtained from 1D (1H , ^{13}C , and DEPT) experiments and 2D (COSY, HSQC and HMBC). The presence of two anomeric protons at δ_H 4.32 and 4.33 ppm with large coupling constants $J = 7.9$ and 6.8 correlates directly through one bond length in HSQC to their carbons at δ_C 103.1 and 105.1 ppm indicating the presence of β -D-glucose and α -L-arabinose respectively. Additionally two oxymethylene protons appeared at δ_H 3.76

Table 3 Effect of *A. lebeck* total extract (Total) and fractions on serum marker enzymes of control and experimental rats.

Treatment (n = 5)	Biochemical parameters									
	AST (units/l)	% Change	ALT (units/l)	% Change	GGT (units/l)	% Change	ALP (units/l)	% Change	Bilirubin (mg/dl)	% Change
Normal	106.01 ± 5.44		29.48 ± 1.50		3.55 ± 0.27		283.00 ± 14.36		0.53 ± 0.02	
CCl ₄	297.66 ± 10.01 ^{***,a}		192.5 ± 5.70 ^{***,a}		10.90 ± 0.41 ^{***,a}		503.66 ± 14.84 ^{***,a}		2.22 ± 0.16 ^{***,a}	
Silymarin	119.83 ± 5.68 ^{***,b}	59.72	100.68 ± 4.27 ^{***,b}	47.69	6.28 ± 0.29 ^{***,b}	42.36	372.00 ± 13.03 ^{***,b}	36.14	1.08 ± 0.04 ^{***,b}	51.49
Total 200 mg	163.16 ± 5.05 ^{***,b}	45.18	139.50 ± 3.76 ^{***,b}	27.53	8.31 ± 0.30 ^{***,b}	23.91	452.50 ± 5.97 ^{*,b}	10.15	1.33 ± 0.04 ^{***,b}	40.04
Total 400 mg	142.83 ± 4.72 ^{***,b}	52.01	127.66 ± 3.48 ^{***,b}	33.67	7.66 ± 0.22 ^{***,b}	29.67	408.50 ± 7.57 ^{***,b}	18.89	1.15 ± 0.04 ^{***,b}	48.05
Normal	106.85 ± 4.18		30.95 ± 1.20		4.96 ± 0.19		337.66 ± 6.11		0.54 ± 0.02	
CCl ₄	331.83 ± 9.78 ^{***,a}		288.83 ± 11.01 ^{***,a}		13.40 ± 0.56 ^{***,a}		598.16 ± 8.97 ^{***,a}		2.33 ± 0.09 ^{***,a}	
Silymarin	149.66 ± 8.04 ^{***,b}	54.89	108.63 ± 7.47 ^{***,b}	62.38	10.40 ± 0.36 ^{***,b}	22.39	420.50 ± 6.23 ^{***,b}	29.70	1.03 ± 0.05 ^{***,b}	55.79
<i>n</i> -Hexane fraction 50 mg	284.66 ± 10.48 ^{*,b}	14.22	240.00 ± 8.61 ^{*,b}	16.91	11.93 ± 0.29 ^b	10.97	564.33 ± 14.72 ^b	5.66	2.05 ± 0.13 ^b	12.01
<i>n</i> -Hexane fraction 100 mg	212.50 ± 9.37 ^{***,b}	35.96	183.83 ± 8.04 ^{***,b}	36.35	7.40 ± 0.57 ^b	44.77	531.33 ± 22.83 ^{*,b}	11.17	1.95 ± 0.10 ^{*,b}	16.31
Normal	101.33 ± 3.08		27.36 ± 1.51		4.73 ± 0.35		326.50 ± 10.55		0.53 ± 0.01	
CCl ₄	319.83 ± 9.11 ^{***,a}		248.50 ± 10.00 ^{***,a}		12.66 ± 0.58 ^{***,a}		606.83 ± 9.29 ^{***,a}		2.25 ± 0.10 ^{***,a}	
Silymarin	148.83 ± 6.97 ^{***,b}	53.46	108.51 ± 5.03 ^{***,b}	56.33	6.01 ± 0.18 ^{***,b}	52.53	401.50 ± 9.29 ^{***,b}	33.84	0.98 ± 0.04 ^{***,b}	56.44
CHCl ₃ fraction 50 mg	300.83 ± 9.18 ^b	5.94	280.50 ± 7.21 ^b	–	12.31 ± 0.49 ^b	–	596.66 ± 12.58 ^b	–	1.98 ± 0.04 ^{*,b}	12
CHCl ₃ fraction 100 mg	273.66 ± 8.89 ^{***,b}	14.43	237.16 ± 13.47 ^{*,b}	4.56	8.40 ± 0.39 ^{***,b}	33.65	510.33 ± 7.13 ^{***,b}	15.90	1.53 ± 0.07 ^{***,b}	32
Normal	109.25 ± 4.25		28.40 ± 1.66		5.21 ± 0.21		312.16 ± 10.36		0.54 ± 0.01	
CCl ₄	304.66 ± 7.21 ^{***,a}		282.50 ± 8.98 ^{***,a}		11.83 ± 0.60 ^{***,a}		586.83 ± 10.36 ^{***,a}		2.75 ± 0.05 ^{***,a}	
Silymarin	137.83 ± 3.93 ^{***,b}	54.76	107.16 ± 5.16 ^{***,b}	62.06	6.53 ± 0.23 ^{***,b}	44.80	401.33 ± 9.69 ^{***,b}	31.61	1.50 ± 0.05 ^{***,b}	45.45
<i>n</i> -Butanol fraction 50 mg	223.33 ± 8.94 ^{***,b}	26.69	224.66 ± 16.43 ^{*,b}	20.47	9.96 ± 0.29 ^{*,b}	15.80	577.50 ± 13.48 ^b	–	2.52 ± 0.08 ^b	8.36
<i>n</i> -Butanol fraction 100 mg	193.33 ± 6.43 ^{***,b}	36.54	145.33 ± 4.55 ^{***,b}	48.56	8.86 ± 0.45 ^{***,b}	25.10	532.00 ± 11.98 ^{***,b}	9.34	2.15 ± 0.09 ^{***,b}	21.82

* $p < 0.05$.** $p < 0.01$.*** $p < 0.001$.^a Compared to normal saline group.^b Compared to Carbon tetrachloride group.

Table 4 Effect of *A. lebbeck* fractions on serum lipid metabolism and serum lipoproteins of control and experimental rats.

Treatment (n = 5)	Cholesterol (mg/dl)	% Change	Triglycerides (mg/dl)	% Change	HDL (mg/dl)	% Change	LDL (mg/dl)	% Change	VLDL (mg/dl)	% Change
Normal	105.16 ± 4.52		60.83 ± 2.70		56.06 ± 2.69		36.92 ± 4.76		12.17 ± 0.54	
CCl ₄	175.66 ± 3.42 ^{***,a}		150.33 ± 3.94 ^{***,a}		25.78 ± 1.78 ^{***,a}		119.81 ± 4.83 ^{***,a}		30.06 ± 0.78 ^{***,a}	
Silymarin	152.33 ± 5.60 ^{**b}	13.28	127.83 ± 3.41 ^{**b}	14.96	38.33 ± 2.40 ^{**b}	48.68	87.83 ± 7.20 ^{**b}	26.69	25.66 ± 0.68 ^{**b}	14.64
<i>n</i> -Hexane fraction 50 mg	160.50 ± 6.30 ^b	–	141.00 ± 3.56 ^b	–	33.38 ± 1.80 ^{*b}	29.48	98.91 ± 6.81 ^{*b}	17.44	28.20 ± 0.71 ^b	–
<i>n</i> -Hexane fraction 100 mg	155.00 ± 7.15 ^{*b}	11.76	131.83 ± 4.07 ^{*b}	12.31	35.35 ± 2.75 ^{*b}	37.12	93.38 ± 8.98 ^{*b}	21.86	26.36 ± 0.81 ^{**b}	12.31
Normal	103.96 ± 4.93		68.40 ± 2.04		56.21 ± 2.08		34.07 ± 5.48		13.68 ± 0.40	
CCl ₄	189.66 ± 6.76 ^{***,a}		170.66 ± 6.11 ^{***,a}		26.66 ± 1.02 ^{***,a}		128.96 ± 6.20 ^{***,a}		34.03 ± 1.22 ^{***,a}	
Silymarin	148.66 ± 6.72 ^{**b}	21.61	123.66 ± 4.42 ^{***,b}	27.54	42.28 ± 2.05 ^{***,b}	58.58	83.41 ± 6.81 ^{***,b}	35.32	24.73 ± 0.88 ^{***,b}	27.33
CHCl ₃ fraction 50 mg	165.16 ± 4.47 ^{*b}	12.91	146.16 ± 4.00 ^{*b}	14.36	40.51 ± 2.64 ^{***,b}	51.95	100.00 ± 4.73 ^{*b}	22.46	29.23 ± 0.80 ^{*b}	14.11
CHCl ₃ fraction 100 mg	144.33 ± 4.12 ^{***,b}	23.90	117.66 ± 4.91 ^{***,b}	31.05	42.28 ± 1.68 ^{***,b}	58.58	78.51 ± 4.58 ^{***,b}	39.12	23.53 ± 0.98 ^{***,b}	30.86
Normal	100.63 ± 4.32		70.13 ± 3.61		58.61 ± 2.79		28.00 ± 5.32		14.02 ± 0.72	
CCl ₄	196.83 ± 7.42 ^{***,a}		172.83 ± 4.32 ^{***,a}		23.10 ± 1.44 ^{***,a}		139.16 ± 6.74 ^{***,a}		34.56 ± 0.86 ^{***,a}	
Silymarin	148.66 ± 6.72 ^{**b}	24.47	123.66 ± 4.42 ^{***,b}	28.45	42.28 ± 2.05 ^{***,b}	83.03	83.41 ± 6.81 ^{***,b}	40.06	24.73 ± 0.88 ^{***,b}	28.44
<i>n</i> -Butanol fraction 50 mg	203.00 ± 10.27 ^b	–	159.33 ± 3.73 ^{*b}	7.81	34.03 ± 1.69 ^{***,b}	47.31	137.10 ± 10.82 ^b	–	31.86 ± 0.74 ^{*b}	7.81
<i>n</i> -Butanol fraction 100 mg	188.50 ± 5.07 ^b	–	142.50 ± 3.22 ^{***,b}	17.55	41.50 ± 1.80 ^{***,b}	79.65	118.49 ± 4.67 ^{*b}	14.85	28.50 ± 0.64 ^{***,b}	17.53

All values represent mean ± SEM. ANOVA, followed by Dunnett's multiple comparison test.

* $p < 0.05$.

** $p < 0.01$.

*** $p < 0.001$.

^a – as compared to normal saline group.

^b – as compared to Carbon tetrachloride group.

Table 5 Effect of *A. lebbek* fractions on NP-SH, MDA and TP in rat liver.

Treatment (<i>n</i> = 5)	MDA (nmol/g)	NP-SH (nmol/g)	Total protein (g/l)
Normal	0.46 ± 0.04	6.01 ± 0.37	98.61 ± 6.74
CCl ₄	6.37 ± 0.46 ^{***,a}	3.37 ± 0.28 ^{***,a}	25.04 ± 3.41 ^{***,a}
Silymarin	1.89 ± 0.20 ^{***,b}	5.84 ± 0.29 ^{***,b}	59.16 ± 4.50 ^{***,b}
<i>n</i> -Hexane fraction 50 mg	5.31 ± 0.42 ^b	3.92 ± 0.17 ^b	34.28 ± 2.95 ^b
<i>n</i> -Hexane fraction 100 mg	2.98 ± 0.25 ^{***,b}	4.61 ± 0.28 ^{*,b}	51.20 ± 5.56 ^{***,b}
Normal	0.46 ± 0.03	7.19 ± 0.31	131.20 ± 9.47
CCl ₄	7.64 ± 0.35 ^{***,a}	4.35 ± 0.28 ^{***,a}	30.20 ± 2.63 ^{***,a}
Silymarin	2.02 ± 0.21 ^{***,b}	6.25 ± 0.22 ^{***,b}	63.53 ± 4.63 ^{***,b}
CHCl ₃ fraction 50 mg	5.09 ± 0.42 ^{***,b}	3.26 ± 0.16 ^{*,b}	47.98 ± 3.32 ^{***,b}
CHCl ₃ fraction 100 mg	2.87 ± 0.200 ^{***,b}	3.35 ± 0.21 ^{*,b}	72.85 ± 5.80 ^{***,b}
Normal	0.52 ± 0.04	7.20 ± 0.38	128.44 ± 9.21
CCl ₄	5.66 ± 0.54 ^{***,a}	3.61 ± 0.13 ^{***,a}	38.54 ± 2.82 ^{***,a}
Silymarin	1.46 ± 0.19 ^{***,b}	4.99 ± 0.25 ^{***,b}	94.98 ± 11.06 ^{***,b}
<i>n</i> -Butanol fraction 50 mg	4.46 ± 0.29 ^{***,b}	4.30 ± 0.32 ^b	59.24 ± 4.83 ^{***,b}
<i>n</i> -Butanol fraction 100 mg	1.82 ± 0.20 ^{***,b}	4.50 ± 0.30 ^{*,b}	82.19 ± 7.19 ^{***,b}

All values represent mean ± SEM. ANOVA, followed by Dunnett's multiple comparison test.

* $p < 0.05$.

** $p < 0.01$.

*** $p < 0.001$.

^a – as compared to Normal saline group.

^b – as compared to Carbon tetrachloride group.

(dd, $J = 11.1, 5.8$ Hz), 4.11 (dd, $J = 11.5, 1.9$ Hz) and δ_{H} 3.90 (dd, $J = 12.6, 2.1$ Hz), 3.66 (brd, $J = 12.4$ Hz) assigned for Glc-6 and Ara-5. The remaining protons and carbons data for β -D-glucose and α -L-arabinose were matched with those reported (Nakamura et al., 2007) and with the glycosides isolated from the currently studied plant (compounds 5–8) (Nakamura et al., 2008; Yang et al., 2013; Yoshikawa et al., 1996). The linkage between the two sugar moieties was found to be (1 → 6) by clear downfield shift of C-6 of β -D-glucose (δ_{C} 69.5 ppm) and significant three bond correlations, observed in HMBC spectrum, from the protons at δ_{H} 3.76, 4.11 ppm (H-6'a and H-6'b) and the anomeric carbon of arabinose resonating at δ_{C} 105.1 ppm. On the other hand, the linkage, between the farnesyl and the sugar moiety, was proved to be at C-1 of the aglycone by a significant downfield shift of C-1 of the farnesol (δ_{C} 66.7) as well as the three bond correlation, observed in HMBC experiment, between H-1 (δ_{H} 4.21, 4.36) and the β -D-glucose anomeric carbon at δ_{C} 103.0 ppm and the above aforementioned data prove compound 6 to be 1-O-[6-O- α -L-arabinopyranosyl β -D-glucopyranoside]-(2E,6E)-farnesol. It is worth to note that crenuloside derivatives (A–G) have been isolated before from *Guioa crenulata* (Magid et al., 2005).

Based on collective data, compound 9 (2,3-dihydroxy-2,3-dihydrosqualene), is identified here from natural source for the first time. However, it was previously synthesized (Brown and Martens, 1977) and also used as precursor in the synthesis of squalene oxides (D'Accolti et al., 2005).

This study proved that *A. lebbek* is a rich source of terpenoid compounds, where we isolate mono, sesqui and triterpenes derivatives. Moreover the sugar part of the isolated biosides (compounds 4–8) consists of α -L-arabinopyranosyl (1 → 6) β -D-glucopyranoside and this finding is considered as a chemotaxonomic marker for genus *Albizia*.

Acknowledgments

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the Research Group Project No. RG-1437-021.

References

- Abdel-Kader, M.S., Alqasoumi, S.I., 2008. Evaluation of the hepatoprotective effect of the ethanol extracts of *Solanum nigrum*, *Cassia fistula*, *Balanites aegyptiaca* and *Carthamus tinctorius* against experimentally induced liver injury in rats. *Alex. J. Pharm. Sci.* 22, 47–50.
- Abdel-Kader, M.S., Alqasoumi, S.I., Hefnawy, M.M., AlSheikh, A. M., 2010. Hepatoprotective effect and safety studies of *Cleome droserifolia*. *Alex. J. Pharm. Sci.* 24, 12–21.
- Ayurvedic Pharmacopoeia of India, 2001. First ed., Part I, vol. III, Gov. of India, The ministry of health & family welfare, The Controller of Publication, Delhi, pp. 201–202.
- Brown, J., Martens, D., 1977. An assessment of the mobility of squalene in part-aqueous solutions from carbon magnetic resonance spin-lattice relaxation times: comparison with squalene and 2,3-dihydroxy-2,3-dihydrosqualene. *Tetrahedron Lett.* 33, 931–935.
- Burstein, M., Scholnick, H.R., Morfin, R., 1970. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. *J. Lipid Res.* 11, 583–595.
- Carpani, G., Orsini, F., Sisti, M., Verotta, L., 1989. Saponins from *Albizia anthelmintica*. *Phytochemistry* 28, 863–866.
- Chassagne, D., Crouzet, J., Bayonove, C.L., Brillouet, J.M., Baumes, R.L., 1996. 6-O- α -L-Arabinopyranosyl- β -D-glucopyranosides as aroma precursors from passion fruit. *Phytochemistry* 41, 1497–1500.
- D'Accolti, L., Annese, C., Fusco, C., 2005. Direct regio- and stereoselective synthesis of squalene 2,3;22,23-dioxide using dioxiranes. *Tetrahedron Lett.* 46, 8459–8462.

- De Rosa, S., De Giulio, A., Tommonaro, G., 1996. Aliphatic and aromatic glycosides from the cell cultures of *Lycopersicon esculentum*. *Phytochemistry* 42, 1031–1034.
- Edwards, C.R.W., Bouchier, I.A.D., 1991. *Davidson's Principles and Practice Medicine*. Churchill Livingstone Press, UK.
- El-Mousallamy, A.M., 1998. Leaf flavonoids of *Albizia lebbek*. *Phytochemistry* 48, 759–761.
- El Gamal, A., Abd El Halim, M., Kalil, A., Basudan, O., Al-Rehaily, A., Ahmad, M., El Tahir, K., Al-Massarani, S., Abdel-Mageed, W., 2015. A novel β -lactam derivative, albactam from the flowers of *Albizia lebbek* with platelets anti-aggregatory activity in vitro. *Pak. J. Pharm. Sci.* 28, 745–753.
- Farag, M., El Gamal, A., Kalil, A., Al-Rehaily, A., El Mirghany, O., El Tahir, K., 2013. Evaluation of some biological activities of *Albizia lebbek* flowers. *Pharmacol. Pharm.* 4, 473–477.
- Foster, L.B., Dunn, R.T., 1973. Stable reagents for determination of serum triglycerides by a colorimetric Hantzsch condensation method. *Clin. Chim. Acta* 19, 338–340.
- Friedwald, W.T., Levy, R.I., Fredrickson, D.S., 1972. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra centrifuge. *Clin. Chem.* 18, 499–502.
- Gundamaraju, R., Hwi, K.K., Singla, R.K., Vemuri, R.C., Mulapalli, S.B., 2014. Antihyperlipidemic potential of *Albizia amara* (Roxb) Boiv. bark against Triton X-100 induced hyperlipidemic condition in rats. *Pharmacogn. Res.* 6, 267–273.
- Johns, T., Mhoro, E.B., Sanaya, P., Kimanani, E.K., 1994. Herbal remedies of the Batemi of Ngorongoro District, Tanzania: a quantitative appraisal. *Econ. Bot.* 48, 90–95.
- Kang, J., Huo, C.H., Li, Z., Li, Z.P., 2007. New ceramides from the flower of *Albizia julibrissin*. *Chin. Chem. Lett.* 18, 181–184.
- Kasai, R., Fujino, H., Kuzuki, T., Wong, W.H., Goto, C., Yata, N., Tanaka, O., Yasuhara, F., Yamaguchi, S., 1986. Acyclic sesquiterpene oligoglycosides from pericarps of *Sapindus mukurossi*. *Phytochemistry* 25, 871–876.
- Kumar, D., Kumar, S., Kohli, S., Arya, R., Gupta, J., 2011. Antidiabetic activity of methanolic bark extract of *Albizia odoratissima* Benth. in alloxan induced diabetic albino mice. *Asian Pac. J. Trop. Med.* 4, 900–903.
- Liang, H., Tong, W.Y., Zhao, Y.Y., Cui, J.R., Tu, G.Z., 2005. An antitumor compound julibroside J28 from *Albizia julibrissin*. *Bioorg. Med. Chem. Lett.* 15, 4493–4495.
- Liu, J., Tang, Y., Wu, K., Bi, C., Cui, Q., 2012. Conversion of fructose into 5-hydroxymethylfurfural (HMF) and its derivatives promoted by inorganic salt in alcohol. *Carbohydr. Res.* 350, 20–24.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the folin-phenol reagent. *J. Biol. Chem.* 193, 265–275.
- Lu, L., Wu, J., Song, D., Zhao, H., Gu, G., Guo, Y., Lan, J., Xiao, M., 2013. Purification of fructooligosaccharides by immobilized yeast cells and identification of ethyl β -D-fructofuranoside as a novel glycoside formed during the process. *Bioresour. Technol.* 132, 365–369.
- Magid, A.A., Voutquenne-Nazabadioko, L., Bontemps, G., Litaudon, M., Lavaud, C., 2008. Tyrosinase inhibitors and sesquiterpene diglycosides from *Guioa villosa*. *Planta Med.* 74, 55–60.
- Magid, A.A., Voutquenne-Nazabadioko, L., Litaudon, M., Lavaud, C., 2005. Acylated farnesyl diglycosides from *Guioa crenulata*. *Phytochemistry* 66, 2714–2718.
- Migahed, A.M., 1996. *Flora of Saudi Arabia*, fourth ed. King Saud University Press, Riyadh.
- Moon, J.H., Watanabe, N., Sakata, K., Inagaki, J., Yagi, A., Ina, K., Luo, S., 1994. Linalyl β -D-glucopyranoside and its 6'-O-malonate as aroma precursors from *Jasminum sambac*. *Phytochemistry* 36, 1435–1437.
- Moshi, M.J., Kagashe, G.A., Mbwambo, Z.H., 2005. Plants used to treat epilepsy by Tanzanian traditional healers. *J. Ethnopharmacol.* 28, 327–336.
- Nakamura, S., Li, X., Matsuda, H., Ninomiya, K., Morikawa, T., Yamaguti, K., Yoshikawa, M., 2007. Bioactive constituents from Chinese natural medicines. XXVI. Chemical structures and hepatoprotective effects of constituents from roots of *Rhodiola sachalinensis*. *Chem. Pharm. Bull.* 55, 1505–1511.
- Nakamura, S., Li, X., Matsuda, H., Yoshikawa, M., 2008. Bioactive constituents from Chinese natural medicines. XXVIII. Chemical structures of acyclic alcohol glycosides from the roots of *Rhodiola crenulata*. *Chem. Pharm. Bull.* 56, 536–540.
- Pabst, A., Barron, D., Sémon, E., Schreier, P., 1991. Isolation of a novel linalool disaccharide glycoside from raspberry fruit. *Tetrahedron Lett.* 32, 4885–4888.
- Sanjay, K., 2003. Saponins of *Albizia lebbek* in alzheimer, s and parkinson, s disease. *Indian J. Nat. Products (IJNPR)* 19, 42–48.
- Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal. Biochem.* 25, 192205.
- Tripathi, R., Das, P., 1977. Studies on anti-asthmatic and anti-anaphylactic activity of *Albizia lebbek*. *Indian J. Pharmacol.* 9, 189–194.
- Varshney, I., Farooq, M., 1952. The effect of the new saponin of *Albizia lebbek* Benth. on the germination and growth of grains; effect of different concentrations and seasons on grains of wheat. *C.R. Seances Soc. Biol. Fil.* 46 (11–12), 902–904.
- Wen, Q., Lin, X., Liu, Y.X., Xu, X., Liang, T., Zheng, N., Kintoko, K., Huang, R., 2012. Phenolic and lignan glycosides from the butanol extract of *Averrhoa carambola* L. root. *Molecules* 17, 12330–12340.
- Yang, C., Wang, Z., Song, P., Xiao, Y., Meng, Y., Wang, Y., Jiang, H., Kuang, H., 2013. Monoterpenoids from *Acanthopanax sessiliflorus* fruits. *Molecules* 18, 2043–2049.
- Yoshikawa, M., Shimada, H., Shimoda, H., Murakami, N., Yamahara, J., Matsuda, H., 1996. Bioactive constituents of Chinese natural medicines. II. *Rhodiola radix*. Chemical structures and antiallergic activity of rhodiocyanosides A and B from the underground part of *Rhodiola quadrifida* (Pall.) Fisch. et Mey. (Crassulaceae). *Chem. Pharm. Bull. (Tokyo)* 44, 2086–2091.
- Zlatkis, A.B., Zak, B., Boyle, A.J., 1953. A new method for the direct determination of serum cholesterol. *J. Lab. Clin. Med.* 41, 486–492.